Major publications by the Heart Failure team in Glasgow

The Heart Failure Group, with colleagues in the Robertson Centre for Biostatistics, Dundee and internationally, has had a productive fortnight with contributions to three key clinical trials published and presented at major congresses:

American Heart Association (AHA):

GALACTIC-HF: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

DAPA-CKD: Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease

AFFIRM-HF: Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

American College of Rheumatology:

FAST: Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

AHA Scientific Sessions:

SUGAR-DM-HF: Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF) 

 


First published: 4 December 2020